July 31, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

Symbol: STAR

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Outcome of Board Meeting of the Company held on July 31, 2026

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

We are pleased to enclose the Unaudited Financial Results (Consolidated and Standalone) of the Company along with Limited Review Report of the Statutory Auditors for the quarter ended June 30, 2026, as approved by the Board of Directors of the Company at their meeting held today i.e., July 31, 2026.

The Board Meeting commenced at 10:30 hrs IST and concluded at 12:30 hrs IST.

The above information shall be made available on the website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited,**

MANJULA RAMAMURTHY
Digitally signed by MANJULA RAMAMURTHY
Date: 2026.07.31 12:33:53 +05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. as above

Strides Pharma Science Limited
CIN: L24230MH1990PLC057062
Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000
Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199
corpcomm@strides.com; www.strides.com

B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited consolidated financial results of Strides Pharma Science Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Strides Pharma Science Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Strides Pharma Science Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) and its share of the net loss after tax and total comprehensive loss of its associates and joint venture for the quarter ended 30 June 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *“Review of Interim Financial Information Performed by the Independent Auditor of the Entity”,* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I of this limited review report.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial information of 2 Subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 2,190 million, total net profit after tax (before consolidation adjustments) of Rs. 354 million and total comprehensive income (before consolidation adjustments) of Rs. 354 million, for the quarter ended 30 June 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of 25 Subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 1,993 million, total net profit after tax (before consolidation adjustments) of Rs. 72 million and total comprehensive income (before consolidation adjustments) of Rs. 314 million, for the quarter ended 30 June 2026, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of Rs. 13 million and total comprehensive loss of Rs. 13 million, for the quarter ended 30 June 2026 as considered in the Statement, in respect of 3 associates and a joint venture, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

G PRAKASH
Digitally signed by G PRAKASH
Date: 2026.07.31 11:51:02 +05'30'

G Prakash

Partner

Bangalore — Membership No.: 099696

31 July 2026 — UDIN:26099696VNNSHA3389

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of the component	Relationship
1	Amexel Pte. Ltd, Singapore	Subsidiary
2	Aponia Laboratories Inc., United States	Associate
3	Arco Lab Private Limited, India	Subsidiary
4	Asaco Trinity Proprietary Limited, South Africa	Associate (w.e.f. 22 May 2026)
5	Beltapharm S.R.L, Italy	Subsidiary
6	Fairmed Healthcare GmbH, Germany	Subsidiary
7	Neviton Softech Private Limited, India	Subsidiary
8	Neviton Technologies Inc., USA	Subsidiary
9	Pharmapar Inc., Canada	Subsidiary
10	Pivot Path Private Limited	Subsidiary converted into Associate due to loss of control w..e.f 30 June 2026
11	Sihuan Strides (HK) Ltd., Hong Kong	Joint venture
12	Strides Arcolab International Ltd, United Kingdom	Subsidiary
13	Strides Consumer LLC (USA)	Subsidiary
14	Strides Consumer Private Limited, India	Subsidiary
15	Strides Foundation Trust, India	Trust
16	Strides Global Consumer Healthcare Limited, UK	Subsidiary
17	Strides Lifesciences Limited, Nigeria	Subsidiary
18	Strides Netherlands B.V., Netherlands	Subsidiary
19	Strides Nordic ApS, Denmark	Subsidiary

20	Strides Pharma (Cyprus) Limited, Cyrpus	Subsidiary
21	Strides Pharma Asia Pte. Ltd., Singapore	Subsidiary
22	Strides Pharma Canada Inc., Canada	Subsidiary
23	Strides Pharma Global (UK) Ltd, United Kingdom	Subsidiary
24	Strides Pharma Global Pte. Limited, Singapore	Subsidiary
25	Strides Pharma Inc., USA	Subsidiary
26	Strides Pharma International AG, Switzerland (formerly, Fairmed Healthcare AG, Switzerland)	Subsidiary
27	Strides Pharma International Limited, Cyprus	Subsidiary
28	Strides Pharma New Zealand Pty Limited	Subsidiary
29	Strides Pharma SA Pty Ltd, South Africa	Subsidiary
30	Strides Pharma Science Limited, India	Holding
31	Strides Pharma Science Pty Ltd, Australia	Subsidiary
32	Strides Pharma UK Ltd, United Kingdom	Subsidiary
33	SVADS Holdings SA, Switzerland	Subsidiary
34	Trinity Pharma (Pty) Ltd, South Africa	Subsidiary
35	UCL Brands Limited, Kenya	Subsidiary
36	Universal Corporation Limited, Kenya	Associate
37	Vensun Pharmaceuticals, Inc., United States	Subsidiary

STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER ENDED JUNE 30, 2026

Rs. in Million

Sl. No.	Particulars	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	AUDITED (Refer Note 9)	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)
	Continuing operations				
I	Revenue from operations	12,654.07	13,234.70	11,197.36	48,586.83
II	Other income (Refer Note 7)	48.90	81.28	85.83	1,507.13
III	**Total income (I + II)**	**12,702.97**	**13,315.98**	**11,283.19**	**50,093.96**
IV	**Expenses**				
	(a) Cost of materials consumed	4,147.15	4,088.76	2,605.80	15,589.19
	(b) Purchases of stock-in-trade	1,663.81	1,274.46	1,209.13	3,615.36
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(859.08)	(0.77)	627.90	382.75
	(d) Employee benefits expense	2,429.86	2,471.14	2,255.18	9,289.57
	(e) Finance costs	405.61	415.79	474.60	1,785.45
	(f) Depreciation and amortisation expense	563.99	532.49	488.86	2,024.01
	(g) Other expenses	2,974.59	3,004.04	2,318.61	10,457.03
	Total expenses (IV)	**11,325.93**	**11,785.91**	**9,980.08**	**43,143.36**
V	**Profit before exceptional items and tax (III - IV)**	**1,377.04**	**1,530.07**	**1,303.11**	**6,950.60**
VI	Exceptional items (Refer note 4)	631.97	(64.05)	(83.67)	(268.43)
VII	**Profit before tax (V + VI)**	**2,009.01**	**1,466.02**	**1,219.44**	**6,682.17**
VIII	Share of profit/(loss) of joint venture and associates, net of taxes - (net)	(12.85)	14.49	0.99	4.69
IX	**Profit before tax (VII + VIII)**	**1,996.16**	**1,480.51**	**1,220.43**	**6,686.86**
X	**Tax expense**				
	- Current tax	290.06	166.11	108.80	778.76
	- Deferred tax	51.17	21.59	55.70	162.90
	Total tax expense (X)	**341.23**	**187.70**	**164.50**	**941.66**
XI	**Profit for the period/year (IX - X)**	**1,654.93**	**1,292.81**	**1,055.93**	**5,745.20**

STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER ENDED JUNE 30, 2026

Rs. in Million

Sl. No.	Particulars	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	AUDITED (Refer Note 9)	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)
XII	**Other comprehensive income**				
A	(i) Items that will not be reclassified to statement of profit and loss	322.53	(574.71)	820.04	(467.01)
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	(80.81)	118.14	(206.32)	91.12
B	(i) Items that may be reclassified to statement of profit and loss	125.67	606.40	(259.53)	615.31
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	(78.22)	47.21	32.70	200.81
	Total other comprehensive income for the period/year(XII)	**289.17**	**197.04**	**386.89**	**440.23**
XIII	**Total comprehensive income for the period/year (XI + XII)**	**1,944.10**	**1,489.85**	**1,442.82**	**6,185.43**
	Profit for the period/year attributable to:				
	- Owners of the Company	1,569.14	1,269.44	996.08	5,561.93
	- Non-controlling interests	85.79	23.37	59.85	183.27
		1,654.93	**1,292.81**	**1,055.93**	**5,745.20**
	Other comprehensive income for the period/year				
	- Owners of the Company	281.83	195.10	383.90	415.09
	- Non-controlling interests	7.34	1.94	2.99	25.14
		289.17	**197.04**	**386.89**	**440.23**
	Total comprehensive income for the period/year				
	- Owners of the Company	1,850.97	1,464.54	1,379.98	5,977.02
	- Non-controlling interests	93.13	25.31	62.84	208.41
		1,944.10	**1,489.85**	**1,442.82**	**6,185.43**
	Earnings per equity share (face value of Rs. 10/- each)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(1) Basic (in Rs.)	17.02	13.77	10.81	60.34
	(2) Diluted (in Rs.)	17.02	13.77	10.81	60.34
	See accompanying notes to the Financial Results				

STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER ENDED JUNE 30, 2026

Notes:

1 These consolidated financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2 The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2026. The statutory auditor has carried out a limited review of the above results and issued unmodified opinion.

3 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Group's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments.

The CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. "Pharmaceutical". Consequently, the Company has only one reportable segment and accordingly disclosures made at a Group level suffice for compliance with the requirements of Ind AS 108.

Pharmaceutical segment represents the business of development, manufacture and commercialization of pharmaceutical products other than biological drugs.

4 **Exceptional Items:**

Rs. in Million

Particulars	**3 Months ended June 30, 2026**	**Preceding 3 Months ended March 31, 2026**	**Corresponding 3 Months ended in the previous year June 30, 2025**	**Previous year ended March 31, 2026**
	UNAUDITED	**AUDITED (Refer Note 9)**	**UNAUDITED**	**AUDITED**
- Expenses related to product recall and settlements (Refer note 6)	(110.10)	(28.95)	(82.17)	(228.79)
- Impairment and write down of assets	-	(34.71)	(0.02)	(34.70)
- Business combination and restructuring expenses (Refer note 5)	742.07	(0.39)	(1.48)	(4.94)
Total	**631.97**	**(64.05)**	**(83.67)**	**(268.43)**

5 On March 19, 2025, the Board of Directors of the Company approved the demerger of the Life Sciences and Digital Innovation capabilities business of Arco Lab Private Limited ("Arco Lab"), a subsidiary of the Company, into Pivot Path Private Limited ("Pivot Path"), subsidiary of Arco Lab, pursuant to a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The Scheme, approved by the Board of Directors of Arco Lab on May 15, 2025, with an appointed date of April 10, 2025, was approved by the Hon'ble National Company Law Tribunal (NCLT) on May 18 2026 and the scheme was made effective pursuant to ROC filings effective June 1, 2026.

On June 27, 2026,the Board of Directors of the Company, approved the dilution of the Group's controlling stake in Pivot Path to incoming investors for an aggregate consideration of ₹1,000 million. Upon completion of the transaction, the Group's shareholding in Pivot Path reduced to 19.95%, resulting in a loss of control over Pivot Path and the recognition of the retained interest as an investment in associate at fair value as on the date of loss of control. As part of the transaction, the Company entered into a five-year Master Services Agreement with Pivot Path containing minimum revenue commitment and annual price escalation arrangement. The Group recognized a net gain of ₹742.07 million on the transaction, including the fair value remeasurement of its retained interest in Pivot Path, which has been disclosed as an exceptional item in these financial results.

STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER ENDED JUNE 30, 2026

6 On March 31, 2020, US Food and Drug Administration (USFDA or the Agency) issued letters to all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescription(Rx) and over-the-counter (OTC) ranitidine drugs from the market immediately. This step was based on their ongoing investigation of the N-Nitrosodimethylamine (NDMA) impurity in ranitidine medications. As a result, effective April 1, 2020, the Group had ceased further distribution of the product and the recall process is completed.

During the year ended March 31, 2022, USFDA issued a letter to the Group to test for the presence of Azide impurity(s) in Losartan. The Azide impurities are API process impurity(s), with the API supplier also receiving a similar letter from USFDA. The results confirmed the presence of Azide impurity(s) in the batches tested. As a result, the Group recalled specific batches which had the Azide impurity(s).

During the quarter ended June 30, 2026, and previous quarter and year ended March 31, 2026, with respect to the above mentioned recalls, the Group is carrying sufficient provision for sales return and has recorded an amount of Rs. 14.32 million, Rs. 9.59 million and Rs. 54.17 million respectively, towards other expenses related to its product withdrawal and settlements. Furthermore, the expenses recorded also include legal fees incurred by the Group in respect of its ongoing litigations with respect to these recalled products. These amounts, in line with earlier periods, have been recorded as an expense within Exceptional items in the statement of profit and loss during the period.

During the year ended March 31, 2025, the Group voluntarily initiated recall of testosterone due to the presence of trace amounts of Benzene and during the previous year ended March 31, 2026, the Group has successfully relaunched the Product to ensure conformance with the FDA's updated requirements. The Group had received certain complaints which are legal in nature and are under evaluation. Accordingly the Group has created a provision of Rs. 95.78 million, Rs. 19.36 million and Rs.174.62 million towards the recall, settlement and other related expense which has been presented in exceptional items in the Statement of profit and loss during the quarter ended June 30, 2026, and previous quarer and year ended March 31, 2026 respectively, in line with earlier periods.

7 During the previous year ended March 31, 2026, the Company sold its investment property consisting of land and building for a consideration of Rs.1,128.70 million and recorded a profit of Rs.1,021.43 million as other income and the corresponding tax impact is considered as part of tax expense in the statement of profit and loss.

8 **Information on Standalone Results : -** **Rs. in Million**

	Particulars	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	AUDITED (Refer Note 9)	UNAUDITED	AUDITED
	Total Income from continuing operations	5,841.23	6,097.05	5,003.74	23,031.98
	Profit/ (loss) before tax from continuing operations	847.58	265.08	164.03	2,031.01
	Profit/ (loss) after tax from continuing operations	729.28	163.53	133.47	1,836.35

9 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures upto the end of the third quarter of the financial years, which are subjected to limited review.

10 On May 18, 2026, the Board of Directors of the Company has proposed a final dividend of Rs. 5 per equity share which shall result in cash outflow of Rs. 461 million (approx). The proposed dividend is subject to the approval of the shareholders at the Annual General Meeting.

For and on behalf of the Board

KOMANDUR BADREE

Digitally signed by KOMANDUR BADREE
Date: 2026.07.31 11:38:26 +05'30'

Badree Komandur

Managing Director and Group CEO

Bangalore, July 31, 2026

B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited standalone financial results of Strides Pharma Science Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Strides Pharma Science Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Strides Pharma Science Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

G PRAKASH

Digitally signed by G PRAKASH
Date: 2026.07.31 11:57:59 +05'30'

G Prakash

Partner

Bangalore
Membership No.: 099696

31 July 2026
UDIN:26099696ROYOPG1498

STRIDES PHARMA SCIENCE LIMITED
CIN: L24230MH1990PLC057062
Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2026

Rs. in Million

Sl. No.	Particulars	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	AUDITED (Refer note 4)	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)
	Continuing Operations				
	Income				
I	Revenue from operations	5,826.48	6,057.35	4,986.16	21,801.35
II	Other income (Refer note 5)	14.75	39.70	17.58	1,230.63
III	**Total income (I + II)**	**5,841.23**	**6,097.05**	**5,003.74**	**23,031.98**
IV	**Expenses**				
	(a) Cost of materials consumed	3,091.06	2,974.60	2,109.77	10,195.97
	(b) Purchases of stock-in-trade	509.51	158.92	157.48	793.96
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(557.85)	1.09	154.61	110.22
	(d) Employee benefits expense	1,024.01	959.37	940.40	3,816.02
	(e) Finance costs	285.09	266.62	304.48	1,137.68
	(f) Depreciation and amortisation expense	257.28	251.91	221.38	912.38
	(g) Other expenses	1,148.56	1,219.46	951.59	4,034.74
	Total expenses (IV)	**5,757.66**	**5,831.97**	**4,839.71**	**21,000.97**
V	**Profit before exceptional items and tax (III - IV)**	**83.57**	**265.08**	**164.03**	**2,031.01**
VI	Exceptional item(Refer note 6)	764.01	-	-	-
VII	**Profit before tax (V + VI)**	**847.58**	**265.08**	**164.03**	**2,031.01**
VIII	**Tax expense**				
	- Current tax	147.73	56.32	(0.47)	169.95
	- Deferred tax	(29.43)	45.23	31.03	24.71
	Total tax expense (VIII)	**118.30**	**101.55**	**30.56**	**194.66**
IX	**Profit for the period/year (VII - VIII)**	**729.28**	**163.53**	**133.47**	**1,836.35**

STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2026

Rs. in Million

Sl. No.	Particulars	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
		UNAUDITED	AUDITED (Refer note 4)	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)
X	**Other comprehensive income**				
A	(i) Items that will not be reclassified to statement of profit and loss	-	46.48	-	46.48
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	-	(37.88)	-	(37.88)
B	(i) Items that may be reclassified to statement of profit and loss	310.78	(336.71)	(93.57)	(776.28)
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	(78.22)	47.21	32.70	200.81
	Total other comprehensive (loss)/ income, net of tax for the period/year (X)	**232.56**	**(280.90)**	**(60.87)**	**(566.87)**
XI	**Total comprehensive income for the period/year (IX + X)**	**961.84**	**(117.37)**	**72.60**	**1,269.48**
	Earnings per equity share (face value of Rs. 10/- each)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic (Rs.)	7.91	1.77	1.45	19.92
	(b) Diluted (Rs.)	7.91	1.77	1.45	19.92
	See accompanying notes to the Standalone Results				

STRIDES PHARMA SCIENCE LIMITED
CIN: L24230MH1990PLC057062
Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2026

Notes:

1 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2026. The statutory auditor has carried out a limited review of the above results for the quarter ended June 30, 2026 and has issued an unmodified opinion.

3 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Company's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments.

The CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. “Pharmaceutical”. The Company publishes standalone and consolidated financial results. Pursuant to Paragraph 4 of Ind AS 108, Operating Segments, the segment information has been disclosed in the consolidated financial results. Accordingly, no separate segment information is presented in these standalone financial results.

Pharmaceutical segment represents the business of development, manufacture and commercialization of pharmaceutical products other than biological drugs.

4 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which are subjected to limited review.

5 During the previous year ended March 31,2026, the Company sold its investment property consisting of land and building for a consideration of Rs.1,128.70 million and recorded a profit of Rs.1,021.43 million as other income and the corresponding tax impact is considered as part of tax expense in the statement of profit and loss.

STRIDES PHARMA SCIENCE LIMITED
CIN: L24230MH1990PLC057062
Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2026

6 On March 19, 2025, the Board of Directors of the company approved the demerger of the Life Sciences and Digital Innovation capabilities business of Arco Lab Private Limited ("Arco Lab"), a subsidiary of the company, into Pivot Path Private Limited ("Pivot Path"), a subsidiary of Arco Lab, pursuant to a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The Scheme, approved by the Board of Directors of Arco Lab on May 15, 2025, with an appointed date of April 10, 2025, was approved by the Hon'ble National Company Law Tribunal (NCLT) on May 18 2026 and the scheme was made effective pursuant to ROC filings effective June 1, 2026.

On June 27, 2026, the Board of Directors of the company approved the dilution of the Company's stake in Pivot Path to incoming investors for an aggregate consideration of ₹ 1,000 million. Upon completion of the transaction on June 30, 2026 , the Group's shareholding in Pivot Path reduced to 19.95% and the Group ceased to have control over Pivot Path. The transaction also included as a condition precedent, on the transaction the execution of a five-year Master Services Agreement with Pivot Path containing minimum revenue commitment and annual price escalation arrangement. Accordingly, the Company recognized a net gain of ₹ 764.01 million, which has been disclosed as an exceptional item in these financial results.

7 On May 18, 2026, the Board of Directors of the Company has proposed a final dividend of Rs. 5 per equity share which shall result in cash outflow of Rs 461 million (approx). The proposed dividend is subject to approval of the shareholders in Annual General Meeting.

For and on behalf of the Board

KOMANDUR BADREE

Digitally signed by KOMANDUR BADREE
Date: 2026.07.31 11:43:43 +05'30'

Badree Komandur
Managing Director and Group CEO

Bangalore, 31 July 2026